Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update as Shares take Spotlight

Based on the latest filings with the SEC, investors are looking at Harvard Bioscience, Inc. (NASDAQ:HBIO)’s short data and trying to figure out market sentiment on which way the market thinks the stock is moving. The firm has 4.12% of total shares float short, yielding a short ratio of 6.88.

There is no easy answer when attempting to address the tough question of how to best approach the equity market, especially when facing a turbulent investing climate. There are many different schools of thought when it comes to stock trading. Investors may have to first gauge their appetite for risk in order to build a solid platform on which to construct a legitimate strategy. The wealth of available information has made the road a bit smoother to travel for amateur investors. Making the transition to the next level is most likely on the minds of many dedicated investors. Tracking technicals and fundamentals may also help provide a roadmap to help separate the contenders from the pretenders. As we head into the second half of the year, it remains to be seen which way the market will lean. Investors may have to do all the necessary homework in order to find stocks that will thrive under any market conditions. 

When the stock market starts to get volatile, investors might start getting worried about their investments. The natural response is to do something about it and take some action. Sometimes this may be necessary, but sometimes the best way to deal with volatility may be to wait it out and stay the course. It can be scary to watch the portfolio decline, and nobody wants to see their stocks taking a nosedive. Although there is no foolproof strategy to ride out market downturns, investors often agree that having a diversified stock portfolio may be the most logical defense.

RECENT PERFORMANCE AND RECOMMENDATION

Let’s take a look at how the stock has been performing recently.  Over the past twelve months, Harvard Bioscience, Inc. (NASDAQ:HBIO)’s stock was 22.73%.  Over the last week of the month, it was -0.25%, -37.69% over the last quarter, and  -17.35% for the past six months. 

Over the past 50 days, Harvard Bioscience, Inc. stock’s -33.61% off of the high and 5.81% removed from the low.  Their 52-Week High and Low are noted here.  -39.55% away from the high and 37.29% from the low. 

Investing in the stock market often requires individuals to gauge how much risk they are willing to take on for potential reward. Piling on too much risk can put the investor out of their comfort zone. On the flip side, taking on too little risk may not provide the opportunity to receive enough returns to achieve previously stated goals. Finding that perfect balance may come with some first-hand experience that includes some trial and error. 

The consensus analysts recommendation at this point stands at 1.30 on Harvard Bioscience, Inc. (NASDAQ:HBIO).  This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. The same analysts are predicting that the company shares will trade to $8.50 within the next 12-18 months. 

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information. Assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.